MedTrace Logo

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

NCT03032614 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-10-10

No results posted yet for this study

Summary

This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.

Conditions

Interventions

DRUG

Carboplatin

Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.

DRUG

Eribulin

Eribulin Mesylate is a synthetic halichondrin analog.

DRUG

Veliparib

Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Virginia Kaklamani, MD · UT Health San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-30
Primary Completion
2019-03-31
Completion
2020-04-30
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03032614 on ClinicalTrials.gov